Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -59.70% is in line with its 5-year average of -61.99%, near the high end of its 5-year range (-86.95%–-48.09%).
6.12% below its 12-month average of -56.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.52%.
RETURN ON ASSETS (ROA)
-59.70%
RETURN ON ASSETS (ROA) AVG TTM
-56.25%
RETURN ON ASSETS (ROA) AVG 3Y
-61.89%
RETURN ON ASSETS (ROA) AVG 5Y
-61.99%
RETURN ON ASSETS (ROA) AVG 10Y
-128.35%
RETURN ON ASSETS (ROA) AVG 15Y
-167.35%
RETURN ON ASSETS (ROA) AVG 20Y
-412.43%
CURRENT VS TTM AVG
-6.12%
CURRENT VS 3Y AVG
+3.53%
CURRENT VS 5Y AVG
+3.69%
CURRENT VS 10Y AVG
+53.49%
CURRENT VS 15Y AVG
+64.33%
CURRENT VS 20Y AVG
+85.52%
SECTOR MEDIAN · HEALTHCARE
-30.67%
median of 740 covered companies
CURRENT VS SECTOR MEDIAN
-94.62%
vs the sector median at left
Marker Therapeutics, Inc.
Market Cap
$17.01M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$16.99M
Return on Assets (ROA)
-98.29%
TTM Avg
-314.03%
3Y Avg
-259.71%
5Y Avg
-198.18%
Market Cap
$17.15M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$16.75M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$16.98M
Return on Assets (ROA)
-30.06%
TTM Avg
65.41%
3Y Avg
-56.95%
5Y Avg
-76.50%
Market Cap
$16.48M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$17.82M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$16.07M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$15.83M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | $17.01M | -59.70% | -56.25% | -61.89% | -61.99% |
| Palatin Technologies, Inc. (PTN)vs › | $16.99M | -98.29% | -314.03% | -259.71% | -198.18% |
| Lipocine Inc. (LPCN)vs › | $17.15M | -49.72% | -28.29% | -39.08% | -40.04% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | -67.58% | -90.98% | -83.38% | -70.12% |
| PAVmed Inc. (PAVM)vs › | $16.98M | -30.06% | 65.41% | -56.95% | -76.50% |
| Dyadic International, Inc. (DYAI)vs › | $16.48M | -116.60% | -66.28% | -71.56% | -63.10% |
| Cosmos Health Inc. (COSM)vs › | $17.82M | -39.68% | -29.52% | -26.86% | -20.28% |
| BioCardia, Inc. (BCDA)vs › | $16.07M | -154.34% | -227.23% | -240.86% | -184.63% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | -38.41% | -84.87% | -95.12% | -75.66% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.43M | -201.89% | -113.65% | -83.24% | -72.72% |
ROA
-59.7%
ROE
-71.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -63.78% |
| 2024-12-31 | -48.73% |
| 2023-12-31 | -48.09% |
| 2022-12-31 | -86.95% |
| 2021-12-31 | -61.46% |
| 2020-12-31 | -62.93% |
| 2019-12-31 | -46.22% |
| 2018-12-31 | -238.09% |
| 2017-12-31 | -211.99% |
| 2016-12-31 | -30.99% |
| 2015-12-31 | -512.63% |
| 2014-12-31 | -13759.53% |
| 2013-12-31 | -7182.73% |
| 2012-12-31 | -5621.23% |
| 2011-12-31 | -596.39% |
| 2010-12-31 | -4372.47% |
| 2009-12-31 | -1249.97% |
| 2008-12-31 | -4150.52% |
| 2007-12-31 | -1394.09% |
| 2006-12-31 | -844.91% |
| 2005-12-31 | -1101.73% |
| 2004-12-31 | -3042.43% |
| 2003-12-31 | -6200.24% |
| 2002-12-31 | -300.09% |
| 2001-12-31 | 0.00% |
| 2000-12-31 | -1069.52% |
| 1999-12-31 | -760.02% |
